Last reviewed · How we verify
Invega Sustenna (PALIPERIDONE PALMITATE)
Invega Sustenna (generic name: PALIPERIDONE PALMITATE) is a Atypical Antipsychotic Small molecule drug developed by Johnson & Johnson. It is currently FDA-approved (first approved 2009) for Schizophrenia.
Invega Sustenna works by blocking a specific channel in the brain that helps regulate electrical activity.
Invega Sustenna (paliperidone palmitate) is a long-acting atypical antipsychotic medication developed by Janssen Pharmaceuticals. It targets the potassium voltage-gated channel subfamily H member 2 to treat schizophrenia. Originally approved by the FDA in 2009, Invega Sustenna is a patented medication with no generic manufacturers available. As an atypical antipsychotic, it is used to manage symptoms of schizophrenia, but its use requires careful consideration of potential side effects. Key safety considerations include the risk of extrapyramidal symptoms, hyperprolactinemia, and QT interval prolongation.
At a glance
| Generic name | PALIPERIDONE PALMITATE |
|---|---|
| Sponsor | Johnson & Johnson |
| Drug class | Atypical Antipsychotic |
| Target | Potassium voltage-gated channel subfamily H member 2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2009 |
| Annual revenue | 3800 |
Mechanism of action
Paliperidone palmitate is hydrolyzed to paliperidone [see Clinical Pharmacology (12.3)]. Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone is unclear. However, the drugs therapeutic effect in schizophrenia could be mediated through combination of central dopamine Type (D2) and serotonin Type (5HT2A) receptor antagonism.
Approved indications
- Schizophrenia
Boxed warnings
- WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA SUSTENNA is not approved for use in patients with dementia-related psychosis. [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA SUSTENNA is not approved for use in patients with dementia-related psychosis. ( 5.1 )
Common side effects
- Injection site reactions
- Somnolence/sedation
- Dizziness
- Akathisia
- Extrapyramidal disorder
- Weight increased
- Nasopharyngitis
- Headache
- Hyperprolactinemia
- Pyrexia
- Fatigue
- Nausea
Drug interactions
- Drugs that may cause orthostatic hypotension
- Strong CYP3A4/P-glycoprotein (P-gp) inducers (e.g., carbamazepine, rifampin, St John's Wort)
- Centrally Acting Drugs and Alcohol
- Levodopa and Other Dopamine Agonists
Key clinical trials
- Substance Misuse To Psychosis for Stimulants (PHASE2,PHASE3)
- A Bioequivalence Study of PP3M in Patients With Schizophrenia (NA)
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
- Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (PHASE4)
- Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia (NA)
- Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia (PHASE4)
- Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 11666573 | 2039-09-24 | Method of Use |
| 9439906 | 2031-01-26 | Method of Use |
| 12128049 | 2038-10-26 | Method of Use |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Invega Sustenna CI brief — competitive landscape report
- Invega Sustenna updates RSS · CI watch RSS
- Johnson & Johnson portfolio CI
Frequently asked questions about Invega Sustenna
What is Invega Sustenna?
How does Invega Sustenna work?
What is Invega Sustenna used for?
Who makes Invega Sustenna?
What is the generic name of Invega Sustenna?
What drug class is Invega Sustenna in?
When was Invega Sustenna approved?
What development phase is Invega Sustenna in?
What are the side effects of Invega Sustenna?
What is Invega Sustenna's annual revenue?
What does Invega Sustenna target?
Related
- Drug class: All Atypical Antipsychotic drugs
- Target: All drugs targeting Potassium voltage-gated channel subfamily H member 2
- Manufacturer: Johnson & Johnson — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Schizophrenia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing